US biotech Vital Therapies (Nasdaq: VTL) and privately-held German firm Immunic Therapeutics are to join forces to focus on advancing the latter’s pipeline of treatments for chronic inflammatory and autoimmune diseases.
The San Diego-based company is expected to acquire all of the outstanding shares in Immunic in exchange for newly-issued shares of Vital Therapies in an all-stock transaction, creating a Nasdaq-listed biopharma called Immunic Inc.
"The proposed transaction will be transformative for Immunic stockholders"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze